These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7380587)

  • 21. [The role of clinical psychiatry in the development of new drugs].
    Benkert O; Hippius H
    Arzneimittelforschung; 1975 Jul; 25(7a):1195-206. PubMed ID: 1242348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teaching mental health skills to general practitioners and medical officers.
    Goldberg D; Gask L
    Seishin Shinkeigaku Zasshi; 2002; 104(9):741-7. PubMed ID: 12481442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rating scales in psychopharmacology. Statistical aspects.
    Bech P
    Acta Psychiatr Belg; 1988; 88(4):291-302. PubMed ID: 3078609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Taxonomy and assessment of psychological investigation methods in psychotropic drug trials (author's transl)].
    Baumann U; Seidenstücker G
    Pharmakopsychiatr Neuropsychopharmakol; 1977 May; 10(3):165-75. PubMed ID: 360241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of generalized anxiety: new pharmacologic approaches].
    Boulenger JP
    Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process.
    Linden M
    Psychopharmacol Bull; 1993; 29(1):51-6. PubMed ID: 8378512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing phase II studies in the context of a programme of clinical research.
    Whitehead J
    Biometrics; 1985 Jun; 41(2):373-83. PubMed ID: 4027320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview.
    Matson JL; Neal D
    Res Dev Disabil; 2009; 30(3):572-86. PubMed ID: 18845418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prescription of drugs without registered indication].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):245-54. PubMed ID: 15136945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of psychotropic drugs: implications for power analysis.
    Davis JM; Janicak PG; Wang Z; Gibbons RD; Sharma RP
    Psychopharmacol Bull; 1992; 28(2):151-5. PubMed ID: 1513917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.